ProQR TherapeuticsPRQR
PRQR
About: ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Employees: 166
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more call options, than puts
Call options by funds: $66K | Put options by funds: $33K
5% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 19
3.8% less ownership
Funds ownership: 43.05% [Q4 2024] → 39.25% (-3.8%) [Q1 2025]
16% less funds holding
Funds holding: 76 [Q4 2024] → 64 (-12) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
53% less capital invested
Capital invested by funds: $118M [Q4 2024] → $54.9M (-$62.8M) [Q1 2025]
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
116%
upside
Avg. target
$7.50
223%
upside
High target
$9
288%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Timur Ivannikov | 245%upside $8 | Overweight Reiterated | 27 Jun 2025 |
JMP Securities Jonathan Wolleben | 245%upside $8 | Market Outperform Reiterated | 27 Jun 2025 |
Oppenheimer Andreas Argyrides | 288%upside $9 | Outperform Maintained | 13 May 2025 |
Evercore ISI Group Gavin Clark-Gartner | 116%upside $5 | Outperform Initiated | 29 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.
Neutral
GlobeNewsWire
1 month ago
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California.
Neutral
GlobeNewsWire
2 months ago
ProQR Announces First Quarter 2025 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2025, and provided a business update.
Neutral
GlobeNewsWire
2 months ago
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT.
Neutral
GlobeNewsWire
2 months ago
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.
Neutral
GlobeNewsWire
2 months ago
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV.
Negative
Zacks Investment Research
3 months ago
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.08 per share a year ago.
Neutral
GlobeNewsWire
3 months ago
ProQR Announces Year End 2024 Operating and Financial Results
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today reported its financial and operating results for the year ended December 31, 2024, and provided a business update.
Neutral
GlobeNewsWire
7 months ago
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform.
Neutral
GlobeNewsWire
8 months ago
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the closing of its previously announced underwritten public offering of 18,000,000 ordinary shares (the “Offering”) at a public offering price of $3.50 per share, for total gross proceeds of $63.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. All of the shares in the Offering were sold by ProQR.
Charts implemented using Lightweight Charts™